The most commonly reported side effects of sodium phosphate monobasic anhydrous include no adverse event, expired product administered, and meningitis viral, based on 2 FDA adverse event reports from 2014 to 2019.
Percentages show how often each reaction appears relative to total reports for sodium phosphate monobasic anhydrous.
These are voluntary reports and do not establish that sodium phosphate monobasic anhydrous caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside sodium phosphate monobasic anhydrous. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
50.0% of sodium phosphate monobasic anhydrous adverse event reports involve female patients and 50.0% involve male patients. The largest age group is child at 100%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking sodium phosphate monobasic anhydrous when the adverse event was reported.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.